The American Medical Association (AMA), which is holding its annual meeting this week in Chicago, Illinois, has issued a call for intensified oversight of the pharmacy benefit manager (PBM) industry.
The American Medical Association (AMA), which is holding its annual meeting this week in Chicago, Illinois, has issued a call for intensified oversight of the pharmacy benefit manager (PBM) industry.
“It’s time to pull back the curtain on pharmacy benefit managers and how their practices negatively impact patients,” said Russell Kridel, MD, a member of the AMA board of trustees, in a statement announcing adoption of the policy. “How is it that PBMs and health plans profit from negotiated discounts on prescription drugs while patients pay co-pays based on high drug list prices that even the plans themselves are not paying? Because of market concentration and lack of transparency, patients and physicians are essentially powerless in the face of PBM pricing and coverage decisions,” he added.
According to the AMA, PBMs have similar roles to insurers, yet face no similar oversight, and are hampering policymakers’ efforts to reduce drug costs with their “byzantine” confidential contracts that drive increased costs for drugs without justification.
The new policy calls for active regulation of PBMs by state departments of insurance, application of rebates to drug prices at the point of sale, efforts to ensure that no patients are discriminated against in benefit design, and increased transparency in how direct and indirect remuneration fees are calculated.
AMA also calls for increased PBM transparency, including disclosure of information on topics like rebates, discounts, and utilization; pharmacy and therapeutics committee information; and formulary information, which AMA says should be made available to patients and prescribers at the point of care.
AMA says that it will develop model legislation addressing state-level regulation of PBMs for policymakers to use.
In addition to its attempt to promote policy solutions, the AMA also seeks to get patients involved; the organization’s new policy is linked with AMA’s TruthinRx campaign, a resource for patients to learn about what influences the price of drugs, how drug prices for products like insulin are increasing over time despite competition, and the role of PBMs in negotiating discounts and rebates with drug makers.
Competitive Pricing in Biosimilars: How Adalimumab Could Shape the Industry
Published: October 29th 2024 | Updated: October 29th 2024Sophia Humphreys, PharmD, MHA, BCBBS, of Sutter Health notes that although initial adoption of adalimumab biosimilars remained low in 2023, competitive pricing pressures have already benefited patients and the health care sector.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
FDA and Industry Experts Unpack Biosimilar Device Requirements
October 23rd 2024At the GRx+Biosims 2024 conference, a panel of industry experts and FDA officials discussed evolving device requirements for biosimilars and interchangeable biosimilars, highlighting new approaches to comparative use human factors studies, regulatory challenges, and alternative validation methods.
Calling for Unified Biosimilar Standards, Stronger Education at GRx+Biosims
October 23rd 2024At the GRx+Biosims conference, a fireside chat highlighted the need to streamline biosimilar development and strengthen industry collaboration, with Sarah Yim, MD, of the FDA, emphasizing education's key role in building trust and adoption.